Latest Funding News

Prime Financial Group has reported robust FY25 results, doubling its revenue run rate and expanding its high-net-worth client base through strategic acquisitions. The company sets ambitious growth targets for FY26 and beyond, underpinned by technology investments and leadership enhancements.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

Everest Metals Corporation has reported impressive rubidium assay results up to 0.79% Rb₂O from its Phase 2 drilling at the Mt Edon Critical Mineral Project, reinforcing the potential for resource expansion ahead of a planned upgrade in early 2026.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

CD Private Equity Fund I reported a $2.6 million net loss for the half-year ended 30 September 2025, driven by foreign exchange impacts and fair value adjustments, while distributing 8 cents per unit amid ongoing portfolio realisations.

Vysarn Limited has reported record FY25 profits and is aiming for a 33% NPBT increase in FY26, driven by acquisitions and progress on the Kariyarra Water Scheme. The company is expanding its national footprint amid growing water demand in mining and infrastructure sectors.

VEEM Limited reported a year of consolidation in FY25 with solid second-half growth driven by new defence contracts and the promising launch of its VEEM Extreme propulsion system. Despite a revenue dip, the company is poised for a stronger FY26 backed by strategic US defence partnerships and product innovation.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

QGold Pty Ltd has initiated an unconditional on-market takeover offer for all shares in Venus Metals Corporation Limited at a 21% premium, aiming to consolidate control and potentially delist the explorer.

QGold Pty Ltd has launched an unconditional on-market takeover offer for all shares of Venus Metals Corporation Limited at a 21% premium, providing shareholders with immediate cash liquidity. The offer, backed by a substantial funding arrangement, signals potential strategic shifts for Venus Metals.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.